# US 2016/0354401 A1 · Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354401 A1
- Document ID: US20160354401A1
- Status: Published application
- Kind: A1
- Application number: 15/239,614
- Filed: 2016-08-17
- Published: 2016-12-08
- Earliest claimed: 2012-03-30
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Byeong-Chel Lee
- Web page: https://patentgrep.com/patent/US20160354401A1

## CPC

- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/664: Amides of phosphorus acids
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides for compositions and methods for administering one or more UDP compound, alone or in combination with another hematopoietic progenitor cell mobilizing compound (for example, but not limited to G-CSF), to mobilize hematopoietic progenitor cells for transplant or other purposes. The methods of the invention may be particularly advantageous as applied to improve the stem cell yield in so-called “poor mobilizing” patients.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A pharmaceutical composition comprising a uridine diphosphate (UDP) compound and a second hematopoietic cell mobilizing compound.

### Claim 29

A pharmaceutical composition comprising a uridine diphosphate (UDP) compound and a second hematopoietic cell mobilizing compound, in an amount effective to mobilize hematopoietic stem cells from the bone into peripheral circulation of a subject in need thereof.

### Claim 30 (depends on 28)

The pharmaceutical composition of claim 28, where the UDP compound is UDP-glucose.

### Claim 31 (depends on 28)

The pharmaceutical composition of claim 28, where the UDP compound is UDP.

### Claim 32 (depends on 28)

The pharmaceutical composition of claim 28, where the UDP compound is selected from the group consisting of UDP-galactose, UDP-N-acetylglucosamine, UDP-glucuronic acid, 5′-O-[[[[(2″,3″,4″,6″-tetra-O-benzoyl-α-D-glucopyranosyl)oxy]carbonyl]amino]sulfonyl]uridine (P536), UDP-6S-6C-methylglucose, UDP-6R-6C-methylglucose, Diphosphoric acid 1-α-D-glucopyranosyl ester 2-[(4′-methylthio)uridin-5″-yl] ester disodium salt (MRS 2690), a mixture of one or more of the aforelisted compounds with UDP glucose or UDP, and a mixture of two or more of the foregoing.

### Claim 33 (depends on 28)

The pharmaceutical composition of claim 28, where the second hematopoietic cell mobilizing compound is granulocyte colony stimulating factor.

### Claim 34 (depends on 28)

The pharmaceutical composition of claim 28, where the second hematopoietic cell mobilizing compound is selected from the group consisting of poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D glucopyranose (PGG) β-glucan, 1,1′-[1,4-phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane] (AMD3100), cyclophosphamide, fucoidan, and a mixture thereof.

### Claim 35 (depends on 28)

The pharmaceutical composition of claim 28, where the subject in need thereof is going to have radiation therapy or chemotherapy.

### Claim 36 (depends on 28)

The pharmaceutical composition of claim 28, where the subject in need thereof has received chemotherapy.

### Claim 37 (depends on 28)

The pharmaceutical composition of claim 28, where the subject in need thereof is being prepared to donate hematopoietic stem progenitor cells.

### Claim 38 (depends on 28)

The pharmaceutical composition of claim 28, where the subject in need thereof has been exposed to a toxic level of radiation.

### Claim 39 (depends on 28)

The pharmaceutical composition of claim 28, where the subject in need thereof suffers from long term bone marrow failure (BMF) or Fanconi's anemia (FA).
